Lucia Parlati, Mehdi Sakka, Aurelia Retbi, Samir Bouam, Lamia Hassani, Jean-François Meritet, Pierre Rufat, Dominique Bonnefont-Rousselot, Rui Batista, Benoit Terris, Agnès Bellanger, Dominique Thabut, Aurore Vozy, Jean-Philippe Spano, Romain Coriat, François Goldwasser, Selim Aractingi, Philippe Sogni, Stanislas Pol, Vincent Mallet
BACKGROUND & AIMS: There is concern about the burden of liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). METHODS: In a retrospective cohort study, we evaluated the likelihood of grade 3/4 liver injury, of grade 3/4 cholestatic liver injury, and of liver failure, as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5, following treatment with ICIs. We compared these occurrences with a group of cancer patients who were propensity-matched and treated with conventional chemotherapy...
December 2023: JHEP reports: innovation in hepatology